Peptic Ulcer Disease

Primary Care - Clinics in Office Practice

Volumn 38, Issue 3, 2011, Pages 383-394

  Najm, Wadie I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Duodenal ulcers; Gastric ulcers; Helicobacter pylori

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AZITHROMYCIN; BISMUTH SALICYLATE; CIMETIDINE; CLARITHROMYCIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; SUCRALFATE; TETRACYCLINE;

ABDOMINAL PAIN; BALLOON DILATATION; CAUSAL ATTRIBUTION; CLINICAL FEATURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM DISEASE; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPIC THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTRIC SUCTION; GASTROINTESTINAL RADIOGRAPHY; HELICOBACTER INFECTION; HUMAN; INCIDENCE; INFECTION RISK; LAPAROSCOPIC SURGERY; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; STOMACH HEMORRHAGE; STOMACH OBSTRUCTION; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTINENTAL POPULATION GROUPS; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HUMANS; PEPTIC ULCER; RISK FACTORS; UNITED STATES;

EID: 80052375733     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2011.05.001     Document Type: Review

References (51)

1. Aro P., Storskrubb T., Ronkainen J., et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006, 163(11):1025-1034.
2. Garrow D., Delegge M.H. Risk factors for gastrointestinal ulcer disease in the US population. Dig Dis Sci 2010, 55(1):66-72.
3. Sung J.J.Y., Kuiperse J., El-Serag H.B. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009, 29:938-946.
4. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori Infection. Clinical Microbilology Reviews 2006, 19(3):449-490.
5. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007, 132(7):2320-2327.
6. Kitchens D.H., Binkley C.J., Wallace D.L., et al. Heficobacter pyfori infection in people who are intellectually and developmentally disabled: a review. Spec Care Dentist 2007, 27(4):127-133.
7. Manuel D., Cutler A., Goldstein J., et al. Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications. Aliment Pharmacol Ther 2007, 25(12):1423-1427.
8. Post P.N., Kuipers E.J., Meijer G.A. Declining incidence of peptic ulcer but not of its complications: a nationwide study in The Netherlands. Aliment Pharmacol Ther 2006, 23(11):1587-1593.
9. Kang J.Y., Elders A., Majeed A., et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006, 24(1):65-79.
10. Makola D., Peura D.A., Crowe S.E. Helicobacter pylori infection and related gastrointestinal diseases. J Clin Gastroenterol 2007, 41(6):548-558.
11. Hobsley M., Tovey F.I., Holton J. Precise role of H pylori in duodenal ulceration. World J Gastroenterol 2006, 12(40):6413-6419.
12. Bardou M., Barkun A.N. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010, 77(1):6-12.
13. Boers M., Tangelder M.J., van Ingen H., et al. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007, 66(3):417-418.
14. Layton D., Souverein P.C., Heerdink E.R., et al. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. Drug Saf 2008, 31(2):143-158.
15. Hooper L., Brown T.J., Elliott R., et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004, 329(7472):948.
16. Laine L., Curtis C.S., Cryer B., et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programm: a randomised comparison. Lancet 2007, 369(9560):465-473. for the MEDAL Steering Committee.
17. Goldstein J.L., Lowry S.C., Lanza F.L., et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective nonsteroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2006, 23(10):1489-1498.
18. Ramakrishnan K., Salinas R.C. Peptic ulcer disease. Am Fam Physician 2007, 76(7):1005-1012.
19. Barkun A., Leontiadis G. Systematic review of the symptom burden, quality-of-life impairment, and costs associated with peptic ulcer disease. Am J Med 2010, 123(4):358-366.
20. Hilton D., Iman N., Burke G.J., et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001, 96(2):380-384.
21. Lu C.L., Chang S.S., Wang S.S., et al. Silent peptic ulcer disease: frequency, factors leading to silence, and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc 2004, 60(1):34-38.
22. Yuan Y., Padol I.T., Hunt R.H. Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol 2006, 3(2):80-89.
23. Franceschi M., Di Mario F., Leandro G., et al. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 2009, 23(6):839-848.
24. Nahon S., Pariente A., Faroux R., et al. Prognosis of upper gastrointestinal bleeding in the oldest-old patients: a post hoc analysis of a prospective study. J Am Geriatr Soc 2010, 58(5):989-990. Association Nationale des Gastroentérologues des Hôpitaux Généraux.
25. Sung J.J., Tsoi K.K., Ma T.K., et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010, 105(1):84-89.
26. Nahon S., Pariente A., Nalet B., et al. Causes of mortality related to peptic ulcer bleeding in a prospective cohort of 965 French patients: a plea for primary prevention. Am J Gastroenterol 2010, 105(8):1902-1903. group of investigators of the ANGH (Association Nationale des Gastroentérologues des Hôpitaux Généraux).
27. Laine L., McQuaid K.R. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009, 7(1):33-47.
28. Sung J.Y. Current management of peptic ulcer bleeding. Nat Clin Pract Gastroenterol Hepatol 2006, 3(1):24-32.
29. Cheung F.K., Lau J.Y. Management of massive peptic ulcer bleeding. Gastroenterol Clin North Am 2009, 38(2):231-243.
30. Lau J.Y., Sung J.J., Lam Y.H., et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999, 340(10):751-756.
31. Svanes C. Trends in perforated peptic ulcer: incidence, etiology, treatment, and prognosis. World J Surg 2000, 24(3):277-283.
32. Ng E.K., Lam Y.H., Sung J.J., et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000, 231(2):153-158.
33. Bhogal R.H., Athwal R., Durkin D., et al. Comparison between open and laparoscopic repair of perforated peptic ulcer disease. World J Surg 2008, 32(11):2371-2374.
34. Boey J., Choi S.K., Poon A., et al. Risk stratification in perforated duodenal ulcers. A prospective validation of predictive factors. Ann Surg 1987, 205(1):22-26.
35. Donovan A.J., Berne T.V., Donovan J.A. Perforated duodenal ulcer: an alternative therapeutic plan. Arch Surg 1998, 133(11):1166-1171.
36. Shone D.N., Nikoomanesh P., Smith-Meek M.M., et al. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995, 90(10):1769-1770.
37. Jaffin B.W., Kaye M.D. The prognosis of gastric outlet obstruction. Ann Surg 1985, 201(2):176-179.
38. Kozarek R.A., Botoman V.A., Patterson D.J. Long-term follow-up in patients who have undergone balloon dilation for gastric outlet obstruction. Gastrointest Endosc 1990, 36(6):558-561.
39. Yusuf T.E., Brugge W.R. Endoscopic therapy of benign pyloric stenosis and gastric outlet obstruction. Curr Opin Gastroenterol 2006, 22(5):570-573.
40. Brown T.J., Hooper L., Elliott R.A., et al. A comparison of the cost-effectiveness of five strategies for the prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006, 10(38):1-183.
41. Lazzaroni M., Porro G.B. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009, 69(1):51-69.
42. Lanas A., Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007, 23(1):163-173.
43. Helicobacter pylori and peptic ulcer disease. The key to cure. Available at: Accessed June 20, 2011. http://www.cdc.gov/ulcer/keytocure.htm%23treatment.
44. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007, 56(6):772-781.
45. Luther J., Higgins P.D., Schoenfeld P.S., et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010, 105(1):65-73.
46. Jafri N.S., Hornung C.A., Howden C.W. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008, 148(12):923-931.
47. Michelfelder A.J., Lee K.C., Bading E.M., et al. Integrative medicine and gastrointestinal disease. Prim Care 2010, 37(2):255-267. Clinics in Office Practice.
48. Hurduc V., Plesca D., Dragomir D., et al. A randomized open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr 2009, 98(1):127-131.
49. Sachdeva A., Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009, 29(7):720-730.
50. de Bortoli N., Leonardi G., Ciancia E., et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007, 102(5):951-956.
51. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009, 21(1):45-53.